Treatment of Opioid Use Disorder in Office Settings
We are looking for people who have Opioid Use Disorder to see if whether getting methadone treatment or getting buprenorphine treatment in an office helps them stick to their treatment plan.
Why this Research Matters
Being able to get methadone in a regular doctor’s office could help people stay in treatment for opioid use disorder. It could also make methadone easier to get and help reduce unfair differences in who can access it. We need more information on how well office-based methadone works compared to office-based buprenorphine for people starting treatment. We also need to understand what patients and healthcare providers think about this approach, and what might help or limit its use.
What to Expect
If you want to join this study, you will first meet with a member of the research team to see if the study is a good fit for you. You will also fill out questionnaires and give a confidential urine sample for drug testing. If you choose to join, you will be randomly placed into one of two groups, like flipping a coin. One group will get methadone in a pill form, prescribed by a healthcare provider and picked up at the pharmacy. The other group will get buprenorphine in a film form to go under your tongue, prescribed by a healthcare provider and picked up at the pharmacy. Both medications are FDA approved for opioid use disorder treatment. Both groups will get weekly text messages to complete a short questionnaire about their medication and drug use. You can do these questionnaires online or by phone. Each month, you will complete more questionnaires about your drug use and health, give a urine sample, and meet with a research team member in person.
Study Duration
The study will last about 6 months. During that time, you will have a screening visit, up to 6 in-person visits and fill out weekly surveys online or on by phone.
Who can Participate
You may be able to join this study if you:
- Are 18 years or older
- Have opoid use disorder
- Are looking for treatment for opoid use disorder
- Are Kaiser Permanente Colorado member
Study ID
Protocol Number: 23-PRS-238
Compensation Information
Meet the Team
Ingrid Binswanger, MD, MS
Principal Investigator